Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
Inv. presentation
Director comp.
Assertio Therapeutics, Inc (ASRT) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/22/2020 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: "Agreement and Plan of Merger, by and among Assertio Therapeutics, Inc., Assertio Holdings, Inc., and Alligator Merger Sub, Inc",
"Certificate of Merger",
"Amended and Restated By-laws of Assertio Therapeutics, Inc."
05/11/2020 8-K Quarterly results
04/24/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
04/08/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024"
03/17/2020 8-K Asset disposition
Docs: "Agreement and Plan of Merger by and among Assertio Therapeutics, Inc., Alligator Zebra Holdings, Inc., Alligator Merger Sub, Inc., Zebra Merger Sub, Inc. and Zyla Life Sciences",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Form of Voting and Support Agreement by and among Alligator Zebra Holdings, Inc. and certain Zyla stockholders",
"Transition Agreement by and among Assertio Therapeutics, Inc. and Arthur Higgins",
"Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive Chairman and Todd Smith to be Named President and CEO of Combined Company",
"Employee FAQs",
"Investor Presentation"
03/11/2020 8-K Quarterly results
03/09/2020 8-K Quarterly results
02/20/2020 8-K Quarterly results
02/13/2020 8-K Quarterly results
02/07/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Asset Purchase Agreement, by and between Assertio Therapeutics Inc. and Collegium Pharmaceutical, Inc.†",
"Assertio Therapeutics Announces Sale of NUCYNTA Franchise to Collegium Pharmaceutical for $375.0 Million Company Intends to Use Cash Proceeds to Retire its Outstanding Debt Company Intends to Use Improved Balance Sheet to Pursue Business Development, Strategic Partnerships and Investment Opportunities"
01/16/2020 8-K/A Financial Statements and Exhibits
Docs: "Unaudited Pro Forma Financial Information of the Company"
01/13/2020 8-K Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Regulation FD Disclosure, ...
Docs: "Assertio Therapeutics Announces Closing of GraliseSale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance"
12/12/2019 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Asset Purchase Agreement, by and among Assertio Therapeutics Inc., Golf Acquiror LLC and, solely for the purposes set forth therein, Celtic Intermediate S.A",
"Sixth Amendment to Note Purchase Agreement, by and among Assertio Therapeutics, Inc., certain subsidiaries of Assertio Therapeutics, Inc. party thereto, certain noteholders party thereto and Deerfield Private Design Fund III, L.P., as collateral agent",
"Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million"
11/06/2019 8-K Quarterly results
Docs: "Assertio Therapeutics Announces Third-Quarter 2019 Results -- Company Implements New Cost Savings Initiatives Expected to Deliver Annualized Savings of $20.0 Million -- -- Raises Full-Year 2019 Earnings Guidance Ranges -- -- Lowers Full-Year 2019 Neurology Franchise Net Sales Guidance -- -- Reduces Total Debt by $200.0 Million Year to Date -- -- Extends Significant Portion of Convertible Debt Maturity to 2024 --"
10/21/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin"
09/30/2019 8-K Quarterly results
08/14/2019 8-K Regulation FD Disclosure
08/09/2019 8-K Quarterly results
08/09/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "Assertio Therapeutics Announces First-Quarter 2019 Financial Results -- Reports Neurology Franchise Net Sales of $26.3 million -- -- Commercialization Agreement Revenues of $30.9 million -- -- Raises 2019 Earnings Guidance Range and Confirms Neurology Franchise Net Sales Guidance -- -- Significant Debt Reduction --"
05/08/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ASSERTIO THERAPEUTICS, INC. AMENDED AND RESTATED 2014 OMNIBUS INCENTIVE PLAN 1. Plan. Assertio Therapeutics, Inc., a Delaware corporation , originally established the 2014 Omnibus Incentive Plan , effective as of February 19, 2014 . The Original Plan was most recently amended and restated in its entirety effective August 15, 2018 in connection with the Company’s name change and reincorporation. The Original Plan, as amended and restated through August 15, 2018, is hereby further amended and restated in its entirety . This Plan shall continue in effect for a term of 10 years after the Effective Date unless sooner terminated by action of the Board of Directors of the Company. 2. Objectives. This Plan is designed to attract and retain employees and consultants of the Company and its Subsidiar..."
04/01/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/28/2019 8-K Other Events
03/06/2019 8-K Quarterly results
Docs: "Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results -- Reports Neurology Franchise Annual Net Sales of $110.3 million, at the High End of Guidance Range -- -- Files NDA for Long-acting Cosyntropin and Receives FDA Notification of Acceptance -- -- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales --"
02/19/2019 8-K Quarterly results
01/09/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Fourth Amendment to Note Purchase Agreement"
01/07/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "January 2019 About this Presentation The statements that are not historical facts contained in this presentation are forward-looking statements including, but not limited to, statements relating to the commercialization of Gralise, CAMBIA, and Zipsor, royalties associated with Collegium's commercialization of NUCYNTA and NUCYNTA ER, regulatory approval and clinical development of cosyntropin depot, our loan agreements, including our senior secured debt facility, and expectations regarding financial results and potential business and investment opportunities. These forward-looking statements involve significant risks and uncertainties, including risks detailed in the Company's Securities and Exchange Commission filings, including the Company's most recent Annual Report on Form 10-K and most..."
11/08/2018 8-K Quarterly results
Docs: "Assertio Therapeutics Announces Third-Quarter 2018 Financial Results -- Confirms Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Raises Full-Year Earnings Guidance and Confirms Adjusted EBITDA Guidance -- -- Amends and Strengthens Commercial Agreement with Collegium -- -- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End --"
11/08/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment No. 3 to Commercialization Agreement, by and among Assertio Therapeutics, Inc., Collegium Pharmaceutical, Inc., and Collegium NF, LLC",
"Consent, by and among Assertio Therapeutics, Inc., certain purchasers and Deerfield Private Design Fund III, L.P"
10/29/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/13/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Assertio Therapeutics, Inc. Corporate Presentation"
08/28/2018 8-K Entry into a Material Definitive Agreement
08/17/2018 8-K/A Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Depomed Announces Second-Quarter 2018 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy